🏢 Company Overview
-
Founded: 1849, New York City
-
Headquarters: The Spiral, Manhattan, NYC
-
CEO: Albert Bourla
-
Industry: Pharmaceuticals & Biotechnology
-
Employees: ~83,000
-
Website: www.pfizer.com (Wikipedia, Biopharma Boardroom)
Pfizer is a global leader in innovative medicines and vaccines, with a strong presence in oncology, cardiology, immunology, infectious diseases, and rare conditions. The company is actively expanding its digital health and AI capabilities to accelerate drug discovery and improve patient access. (Wikipedia)
📊 Financial Performance (2024 & 2025 Outlook)
-
2024 Revenue: $63.6 billion (+7% YoY)
-
Net Income: $8.02 billion
-
Adjusted EPS: $3.11
-
2025 Revenue Guidance: $61–64 billion
-
2025 Adjusted EPS Guidance: $2.80–$3.00
-
R&D Investment (2025): $10.7–$11.7 billion (Biopharma Boardroom, Investopedia, MarketWatch)
Pfizer achieved $4 billion in cost savings in 2024 and targets $4.5 billion by the end of 2025. The company is also investing in AI and automation to enhance operational efficiency. (MarketWatch)
💊 Key Products & Pipeline Highlights
Approved in 2024–2025:
-
Beqvez (fidanacogene elaparvovec): A one-time gene therapy for hemophilia B, approved in the U.S., Canada, and EU. (Wikipedia)
-
Hympavzi (marstacimab): A first-in-class monoclonal antibody for hemophilia A and B, approved in the U.S. and EU. (Wikipedia)
-
Emblaveo (aztreonam/avibactam): An antibiotic for multidrug-resistant Gram-negative infections, approved in the U.S. and EU. (Wikipedia)
Top-Selling Products:
-
Vyndaqel: Used for treating transthyretin amyloid cardiomyopathy; sales increased by 60% in 2024. (Biopharma Boardroom)
-
Eliquis: An anticoagulant with 13% operational growth. (Biopharma Boardroom)
-
Xtandi: A prostate cancer treatment with 24% growth. (Biopharma Boardroom)
-
Nurtec ODT/Vydura: A migraine therapy with 39% growth. (Biopharma Boardroom)
COVID-19 Products:
-
Comirnaty (vaccine): Revenue declined by 38% in Q4 2024. (Biopharma Boardroom)
-
Paxlovid (antiviral): Sales reached $727 million in Q4 2024. (MarketWatch)
🔄 Strategic Initiatives
-
Acquisitions: In December 2023, Pfizer acquired Seagen for $43 billion to enhance its oncology portfolio. (Wikipedia)
-
Digital Health: Launched the "PfizerForAll" platform in 2025 to improve access to healthcare services, including telehealth and prescription delivery. (Wikipedia)
-
AI Integration: Expanded partnerships with AI firms like Saama and Ignition AI Accelerator to streamline clinical trials and drug development. (Wikipedia)
📈 Stock & Shareholder Information
-
Ticker: PFE (NYSE)
-
Market Cap (April 2025): ~$125.6 billion
-
Dividend: $0.43 per share in Q1 2025
-
Top Institutional Holders: Vanguard, BlackRock, State Street
-
Insider Holdings: CEO Albert Bourla owns over 316,000 shares. (Investopedia)